McAdam LLC Acquires 1,218 Shares of Merck & Co., Inc. (NYSE:MRK)

McAdam LLC lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 7.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,951 shares of the company’s stock after buying an additional 1,218 shares during the period. McAdam LLC’s holdings in Merck & Co., Inc. were worth $2,038,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Patron Partners LLC boosted its stake in shares of Merck & Co., Inc. by 2.1% in the 1st quarter. Patron Partners LLC now owns 10,580 shares of the company’s stock valued at $1,396,000 after purchasing an additional 222 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Merck & Co., Inc. by 10.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 247,338 shares of the company’s stock worth $32,636,000 after purchasing an additional 22,578 shares in the last quarter. G&S Capital LLC acquired a new position in shares of Merck & Co., Inc. during the first quarter valued at about $1,359,000. AMF Tjanstepension AB boosted its stake in Merck & Co., Inc. by 114.2% during the 3rd quarter. AMF Tjanstepension AB now owns 802,384 shares of the company’s stock valued at $91,205,000 after purchasing an additional 427,831 shares during the last quarter. Finally, M&G Plc bought a new stake in Merck & Co., Inc. during the first quarter worth $48,921,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 0.2 %

Shares of Merck & Co., Inc. stock opened at $106.38 on Thursday. Merck & Co., Inc. has a twelve month low of $99.80 and a twelve month high of $134.63. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The company’s 50 day moving average is $113.86 and its 200 day moving average is $121.93. The company has a market cap of $269.44 billion, a price-to-earnings ratio of 118.20, a price-to-earnings-growth ratio of 1.55 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.12. The firm had revenue of $16.10 billion for the quarter, compared to the consensus estimate of $15.87 billion. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the business posted ($2.06) EPS. Research analysts anticipate that Merck & Co., Inc. will post 7.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Truist Financial decreased their price target on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. UBS Group dropped their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Morgan Stanley lifted their target price on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a report on Thursday, July 11th. Barclays lowered their price objective on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday, October 7th. Finally, Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.62.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.